Given 2 Years, Living 13 Strong
Living 13 Years Strong: Debbie’s Stage 4 Lung Cancer Journey of Hope and Persistence
When Debbie was first diagnosed with stage 4 lung cancer, doctors told her she might only have one to two years left. Like many patients, she felt overwhelmed and afraid. But instead of giving up, she sought a second opinion and learned that her cancer carried the BRAF mutation. This discovery opened the door to targeted therapy through a clinical trial—something that gave her options beyond traditional chemotherapy and radiation.
Over the last 13 years, Debbie has faced many treatments, side effects, and setbacks, but also many breaks from therapy where she could live life more fully. She has outlived the predictions and now encourages other patients to stay hopeful, ask questions, and keep pushing for answers. Debbie’s story shows how advances in biomarker testing and targeted therapy can turn what once felt like an “end date” into years filled with milestones and new memories.
Her journey reminds us that no one is defined by statistics. For patients with advanced lung cancer, Debbie is living proof that hope, persistence, and medical progress can lead to more time and better quality of life. (Source: GO2 for Lung Cancer)
New Clues on How Cancer Spreads
New Clues on Cancer Metastasis: How “Shape-Shifting” Cells Spread and Survive
For decades, doctors have known that cancer’s deadliest threat comes not from the original tumor but from metastasis — when cancer spreads to other parts of the body. Up to 90% of cancer deaths are linked to this process. Now, researchers led by Dr. Joan Massagué at Memorial Sloan Kettering are uncovering important insights into how metastatic cells survive, hide, and return to grow new tumors years later. These “shape-shifting” cells act like stem cells, traveling back in time to earlier, more flexible states that allow them to adapt and resist treatment. They can also slip into dormancy, hiding from the immune system until the conditions are right to awaken and spread again.
Scientists are learning that metastatic cells use different strategies depending on the type of cancer and the organ they invade. They can even change their physical shape to avoid being destroyed by the immune system. These discoveries open new possibilities for treatment — from targeting the hidden “time traveler” state, to waking dormant cells so the immune system can attack them, to blocking proteins that allow cancer cells to evade detection. While challenges remain, Dr. Massagué emphasizes that metastasis is no longer an automatic death sentence. With advances in immunotherapy and targeted research, controlling — and in some cases curing — stage 4 cancer is becoming more possible than ever before. (Source: Memorial Sloan Kettering)
Riding Through Cancer: Christy’s Story
Riding My Harley Through Cancer: Christy’s Stage 4 Lung Cancer Story
When Christy Erickson was diagnosed with stage IV lung cancer at just 41, she feared she wouldn’t see her children grow up. But after months of unanswered questions and second opinions, genetic testing revealed her tumor carried an EGFR mutation—opening the door to a targeted therapy called osimertinib. This treatment, born from years of research, gave her what once seemed impossible: more time with her family and the chance to live fully, not just survive.
Christy has faced her journey with courage, faith, and determination. She’s checked off bucket-list dreams, from riding her own Harley to competing in strongman events, and she shares her story to encourage others to advocate for themselves. “Osimertinib gave me time,” she says—time to see her daughter graduate, time to rediscover joy, and time to inspire other patients that even after a stage IV diagnosis, hope and healing are possible. (Source: Winship Cancer Institute of Emory University)
Second Opinions Can Save Lives
Why Getting a Second Opinion for Cancer Can Save Your Life
Being told you have cancer is overwhelming, and it’s easy to feel pressured to start treatment right away. But getting a second opinion can make a huge difference—it may confirm the diagnosis, catch mistakes, or suggest new treatment options. For patients with stage 4 or hard-to-treat lung cancer, this extra step can open the door to advanced therapies and clinical trials not available everywhere.
Specialists at National Cancer Institute-designated centers look deeper than a single test. They review scans, biopsy slides, and genetic testing to match you with the best targeted therapy or immunotherapy. Many doctors welcome second opinions, and sometimes both teams can work together—giving you more support, not less.
Most importantly, a second opinion can give you peace of mind. Knowing your diagnosis and plan have been double-checked helps you move forward with confidence and focus on what matters most: your care and your life. (Source: Winship Magazine)
Read the complete article here >
Karen’s Fight, Eight Years and Counting
When Karen was first diagnosed with lung cancer at age 47, it came as a complete shock. A healthy, never-smoker with no family history, she suddenly found herself facing surgery to remove part of her lung and rounds of chemotherapy. For eight years her scans were clear—until the cancer returned in her ribs. Now living with stage 4 lung cancer, she is facing this new challenge with the same determination she had at the very beginning.
What gives Karen strength is the progress that’s been made in lung cancer research. Eight years ago, her mutation wasn’t even identifiable. Today, doctors not only know what it is, but there are already FDA-approved treatments available. Karen continues to live life fully—biking, traveling, taking classes—and believes every patient deserves to feel this hopeful. Her story is a powerful reminder that advances in treatment are giving people more options, more time, and more hope than ever before. (Source: Karen V. Blog)
What’s Driving Lung Cancer in Nonsmokers?
What’s Driving Lung Cancer in Nonsmokers? Understanding RET-Positive Lung Cancer
Lung cancer isn’t just a smoker’s disease. In fact, up to 20% of lung cancer patients have never smoked, and many are younger women. One reason? Genetic mutations like RET fusions, which can drive cancer growth even without traditional risk factors. This type, called RET-positive lung cancer, is more common in never smokers and doesn’t show up on routine screenings.
That’s why genetic testing (also called biomarker testing) is critical. It can help doctors choose targeted treatments that work better and offer more hope—especially for patients with stage 4 or hard-to-treat lung cancer. Even if you’ve never smoked, if you’re experiencing unusual symptoms or have lung cancer in your family, talk to your doctor about testing. Early detection and personalized care are changing what’s possible. (Source: American Cancer Society, Yale Medicine, J Clin Oncol)
Genetics Study Brings Lung Cancer Hope
A powerful new genetics study is offering fresh hope in the fight against lung cancer — especially for patients with rare mutations and those who’ve never smoked. The Lung Cancer Genetics Study, launched in 2024 by 23andMe and supported by nearly two dozen patient advocacy groups, is collecting genetic and clinical data from thousands of lung cancer patients to help uncover what drives this complex disease. It’s one of the first efforts of its kind to truly center patient voices from the beginning, ensuring that research reflects real-world experiences.
The project began with a friendship between two women living with lung cancer, Ilana Stromberg and Susan Troper Wojcicki, both mothers of five and determined to make a difference. Motivated by the lack of research and funding for lung cancer, especially RET-positive and other biomarker-driven subtypes, they envisioned a national lung cancer registry that could drive discoveries and lead to better, more personalized treatments. Susan’s passing in 2024 makes the study even more meaningful to those involved. Her legacy lives on through this groundbreaking initiative, which is expected to accelerate research and give families facing lung cancer a renewed sense of hope. (Source: 23andMe Blog)
Innovations Bring Hope to Lung Patients
New Lung Cancer Innovations Offering Hope to Patients
At Memorial Sloan Kettering, cutting-edge lung cancer care is changing lives—especially for those with advanced disease. Take Jen Cosgrove, a mother diagnosed with stage 4 lung cancer that had spread. Thanks to precise testing, doctors found her tumor had an ALK gene mutation, which responds well to targeted therapy called alectinib. Jen saw dramatic improvements within days and has been able to share important milestones with her children she once feared missing. MSK’s expert care, innovative treatments, and thorough diagnostics give patients like Jen hope and more time with their loved ones.
New Discoveries in Lung Cancer Detection
MSK researchers are also uncovering new types of lung cancer and better ways to detect it early. For example, they identified a rare form called atypical small cell lung carcinoma in younger patients who never smoked. Early detection remains critical, and MSK is developing noninvasive tools like the “E-nose,” a device that detects cancer-related chemicals in breath, which could make screening easier and less stressful. Lab studies on lung stem cells and tumor growth help scientists understand how cancer starts and grows, leading to better treatments. For patients facing lung cancer, these advances mean earlier diagnosis, more personalized care, and brighter hope for the future. (Source: Memorial Sloan Kettering)
Read the complete article here >
Resources for Living With Stage 4 Cancer
Learn more about topics like lung cancer innovations, along with other important aspects of living with Stage 4 cancer. Become a member of our community to receive inspiring stories, helpful resources, and updates on how we support individuals and families facing advanced-stage cancer. Stay informed with the latest research and gain early access to educational content.
Precision Cancer Testing Brings New Hope
At Memorial Sloan Kettering’s Center for Molecular Oncology, doctors use advanced testing to find the exact changes in a person’s cancer cells. This helps them choose treatments that specifically target those changes, giving patients a better chance at controlling their cancer. Over the past decade, tests like MSK-IMPACT® have made it possible to check for hundreds of genetic changes, even through simple blood tests, helping people with advanced or rare cancers find personalized therapies. But DNA testing doesn’t show everything, so new tests that look at how cancer cells use genes (called RNA tests) and even check all of a person’s genes (whole-genome sequencing) are coming soon. These tools aim to help patients who don’t respond to current treatments and could also guide immunotherapy, which uses the body’s immune system to fight cancer.
This kind of testing can also find inherited gene changes that increase cancer risk, helping families take steps to prevent cancer early. One inspiring example is patient Michael Wolff, a jazz pianist whose rare cancer was identified through molecular testing. Doctors found a gene mutation that led to a drug treatment which quickly stopped his symptoms and shrank his tumors. His success shows how precise testing can save lives and open the door to new treatments for cancers that were once very hard to treat. For patients with stage 4 or difficult cancers, these advances mean more hope for better, tailored care—and the chance for improved quality of life. (Source: Memorial Sloan Kettering)
Young Mom Beats Lung Cancer Odds
Just as 38-year-old Lauren was getting back into shape after becoming a new mom, her life changed overnight. A nagging pain in her neck led to scans that uncovered a mass in her lung—stage 3 lung cancer. She went from running miles to navigating CT scans and the shock of a diagnosis she never imagined. “I remember saying, ‘Am I going to make it to my daughter Elle’s second birthday?’” Lauren recalled.
Motivated by her young daughter, Lauren faced treatment head-on. She preserved her fertility, then began chemotherapy and radiation to shrink the tumors. A portion of her lung was surgically removed after a month of healing. Throughout it all, she clung to her purpose: “Elle gave me the motivation to get up and get infusions when I was feeling my worst.” Genetic testing revealed an EGFR mutation—common in nonsmokers like Lauren and a key to unlocking targeted therapy. Now, with no evidence of disease, Lauren stays vigilant with regular scans and remains a voice of hope.
“Your support literally saves lives,” she says, grateful for both friends and strangers who make research breakthroughs possible. (Source: GO2 for Lung Cancer)
Consider Donating to Advance Research
RET-positive lung cancer is a rare type of cancer driven by a change in a gene called RET, which stands for “rearranged during transfection.” This gene helps control how cells grow and divide. When it fuses with another gene or mutates, it can cause cancer to grow and spread—especially in certain lung and thyroid cancers. Because RET changes are so rare, researchers don’t have enough lab models—called cancer cell lines—to fully study how the cancer behaves or how it becomes resistant to treatment.
One powerful way patients can help is by donating tumor tissue during a biopsy or surgery. That tissue can be used to grow RET-positive cancer cells in the lab, giving scientists tools to test new treatments and develop better, more personalized options. Thanks to the generosity of several RET patients, four new cancer cell lines are now being developed. If you’re a patient, talk to your care team about donating—your gift could move research forward and bring better treatments to others living with RET-driven cancer. (Source: The Happy Lungs Project)
Study Offers Hope for Women with Lung Cancer
A new study is exploring why some treatments don’t work as well for women with squamous cell lung cancer, a common type of non-small cell lung cancer often linked to smoking. This form of lung cancer hasn’t responded well to the newer targeted therapies that help other types of lung cancer. But researcher Dr. Milica Momcilovic is working to change that by studying how hormones like estrogen may affect treatment outcomes in women.
Her early research in lab and animal models shows that a drug called TAK228, which blocks cancer growth signals, works better in male mice than females—possibly because estrogen interferes. When combined with an anti-estrogen drug (similar to what’s used in breast cancer), female tumors responded better. This could eventually lead to more personalized treatments for women with lung cancer, helping doctors choose the right therapies and improving survival and quality of life. (Source: American Lung Association)
